Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia

Blood

Volumn 127, Issue 13, 2016, Pages 1687-1700

  Zhang, Qifang ^a,b   Hossain, Dewan Md Sakib ^a   Duttagupta, Priyanka ^a   Moreira, Dayson ^a   Zhao, Xingli ^a   Won, Haejung ^a   Buettner, Ralf ^a   Nechaev, Sergey ^a   Majka, Marcin ^c   Zhang, Bin ^a   Cai, Qi ^a   Swiderski, Piotr ^a   Kuo, Ya Huei ^a   Forman, Stephen ^a   Marcucci, Guido ^a   Kortylewski, Marcin ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b GUIZHOU MEDICAL UNIVERSITY   (China)

^c JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARGINASE; CYTOSINE GUANINE DINUCLEOTIDE; DECOY OLIGODEOXYNUCLEOTIDE; DINUCLEOTIDE; JANUS KINASE 2 INHIBITOR; LIGAND; OLIGODEOXYNUCLEOTIDE; STAT3 PROTEIN; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; OLIGODEOXYRIBONUCLEOTIDE;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONJUGATE; CONTROLLED STUDY; CYTOPLASM; DENDRITIC CELL; DRUG CYTOTOXICITY; DRUG HALF LIFE; ENDOSOME; GENE EXPRESSION; GENE TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; INTERNALIZATION; MOUSE; NONHUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; REPEATED DRUG DOSE; SERUM; STEM CELL; TUMOR IMMUNITY; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL SURVIVAL; CHEMISTRY; CPG ISLAND; DRUG EFFECTS; DRUG STABILITY; GENE; GENE THERAPY; GENETICS; IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHYSIOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR CELL LINE; TUMOR ESCAPE;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; CPG ISLANDS; DRUG STABILITY; GENES, CDC; GENETIC THERAPY; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; OLIGODEOXYRIBONUCLEOTIDES; SERUM; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR ESCAPE;

EID: 84963553863     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-08-665604     Document Type: Article

References (65)

1. Marabelle A, Kohrt H, Sagiv-Barfi I, et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest. 2013;123(6):2447-2463.
2. Zhang L, Chen X, Liu X, et al. CD40 ligation reverses T cell tolerance in acute myeloid leukemia. J Clin Invest. 2013;123(5):1999-2010.
3. Benekli M, Xia Z, Donohue KA, et al. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood. 2002;99(1):252-257.
4. Irish JM, Hovland R, Krutzik PO, et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell. 2004;118(2):217-228.
5. Benekli M, Baumann H, Wetzler M. Targeting signal transducer and activator of transcription signaling pathway in leukemias. J Clin Oncol. 2009;27(26):4422-4432.
6. Kornblau SM, Tibes R, Qiu YH, et al. Functional proteomic profiling of AML predicts response and survival. Blood. 2009;113(1):154-164.
7. Redell MS, Ruiz MJ, Alonzo TA, Gerbing RB, Tweardy DJ. Stat3 signaling in acute myeloid leukemia: ligand-dependent and-independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood. 2011;117(21):5701-5709.
8. Steensma DP, McClure RF, Karp JE, et al. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia. 2006;20(6):971-978.
9. Al Zaid Siddiquee K, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res. 2008;18(2):254-267.
10. Chakraborty A, White SM, Schaefer TS, Ball ED, Dyer KF, Tweardy DJ. Granulocyte colonystimulating factor activation of Stat3 alpha and Stat3 beta in immature normal and leukemic human myeloid cells. Blood. 1996;88(7):2442-2449.
11. Levine JH, Simonds EF, Bendall SC, et al. Datadriven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis. Cell. 2015;162(1):184-197.
12. Hossain DM, Dos Santos C, Zhang Q, et al. Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity. Blood. 2014;123(1):15-25.
13. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798-809.
14. Kortylewski M, Nechaev S. Cancer therapy using oligonucleotide-based STAT3 inhibitors: will they deliver? Ther Deliv. 2014;5(3):239-242.
15. Leong PL, Andrews GA, Johnson DE, et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA. 2003;100(7):4138-4143.
16. Sen M, Thomas SM, Kim S, et al. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov. 2012;2(8):694-705.
17. Kortylewski M, Swiderski P, Herrmann A, et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol. 2009;27(10):925-932.
18. Zhang Q, Hossain DM, Nechaev S, et al. TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. Blood. 2013;121(8):1304-1315.
19. Kimbrel EA, Davis TN, Bradner JE, Kung AL. In vivo pharmacodynamic imaging of proteasome inhibition. Mol Imaging. 2009;8(3):140-147.
20. Landrette SF, Madera D, He F, Castilla LH. The transcription factor PlagL2 activates Mpl transcription and signaling in hematopoietic progenitor and leukemia cells. Leukemia. 2011;25(4):655-662.
21. Nechaev S, Gao C, Moreira D, et al. Intracellular processing of immunostimulatory CpG-siRNA: Toll-like receptor 9 facilitates siRNA dicing and endosomal escape. J Control Release. 2013;170(3):307-315.
22. Turkson J, Kim JS, Zhang S, et al. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther. 2004;3(3):261-269.
23. Lee H, Herrmann A, Deng JH, et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell. 2009;15(4):283-293.
24. Hossain DM, Pal SK, Moreira D, et al. TLR9-targeted STAT3 silencing abrogates immunosuppressive activity of myeloid-derived suppressor cells from prostate cancer patients. Clin Cancer Res. 2015;21(16):3771-3782.
25. Kortylewski M, Kujawski M, Wang T, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. 2005;11(12):1314-1321.
26. Sadowski HB, Shuai K, Darnell JE Jr, Gilman MZ. A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. Science. 1993;261(5129):1739-1744.
27. Lui VW, Boehm AL, Koppikar P, et al. Antiproliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT) 3: the role of STAT1. Mol Pharmacol. 2007;71(5):1435-1443.
28. Souissi I, Najjar I, Ah-Koon L, et al. A STAT3-decoy oligonucleotide induces cell death in a human colorectal carcinoma cell line by blocking nuclear transfer of STAT3 and STAT3-bound NF-κB. BMC Cell Biol. 2011;12:14.
29. Kortylewski M, Kujawski M, Herrmann A, et al. Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy. Cancer Res. 2009;69(6):2497-2505.
30. Gao C, Kozlowska A, Nechaev S, et al. TLR9 signaling in the tumor microenvironment initiates cancer recurrence after radiotherapy. Cancer Res. 2013;73(24):7211-7221.
31. Kovacic B, Stoiber D, Moriggl R, et al. STAT1 acts as a tumor promoter for leukemia development. Cancer Cell. 2006;10(1):77-87.
32. Schiavone D, Avalle L, Dewilde S, Poli V. The immediate early genes Fos and Egr1 become STAT1 transcriptional targets in the absence of STAT3. FEBS Lett. 2011;585(15):2455-2460.
33. Adach-Kilon A, Swiatek-Machado K, Kaminska B, Dabrowski M. Signal transducer and activator of transcription 1 (Stat1) maintains basal mRNA expression of pro-survival stat3-target genes in glioma C6 cells. J Cell Biochem. 2011;112(12):3685-3694.
34. Yuan J, Wegenka UM, Lütticken C, et al. The signalling pathways of interleukin-6 and gamma interferon converge by the activation of different transcription factors which bind to common responsive DNA elements. Mol Cell Biol. 1994;14(3):1657-1668.
35. Turkson J, Zhang S, Palmer J, et al. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther. 2004;3(12):1533-1542.
36. Souissi I, Ladam P, Cognet JA, et al. A STAT3-inhibitory hairpin decoy oligodeoxynucleotide discriminates between STAT1 and STAT3 and induces death in a human colon carcinoma cell line. Mol Cancer. 2012;11:12.
37. Berthon C, Driss V, Liu J, et al. In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors. Cancer Immunol Immunother. 2010;59(12):1839-1849.
38. Mussai F, De Santo C, Abu-Dayyeh I, et al. Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood. 2013;122(5):749-758.
39. Vasquez-Dunddel D, Pan F, Zeng Q, et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest. 2013;123(4):1580-1589.
40. Narimatsu M, Maeda H, Itoh S, et al. Tissuespecific autoregulation of the stat3 gene and its role in interleukin-6-induced survival signals in T cells. Mol Cell Biol. 2001;21(19):6615-6625.
41. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730-737.
42. Welte T, Zhang SS, Wang T, et al. STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc Natl Acad Sci USA. 2003;100(4):1879-1884.
43. Wernig G, Kharas MG, Okabe R, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617Finduced polycythemia vera. Cancer Cell. 2008;13(4):311-320.
44. Zhang M, Xu CR, Shamiyeh E, et al. A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers. J Clin Pharmacol. 2014;54(4):415-421.
45. Betts BC, Abdel-Wahab O, Curran SA, et al. Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cellstimulated T cells yet preserves immunity to recall antigen. Blood. 2011;118(19):5330-5339.
46. Burel SA, Han SR, Lee HS, et al. Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys. Nucleic Acid Ther. 2013;23(3):213-227.
47. Sen M, Grandis JR. Nucleic acid-based approaches to STAT inhibition. JAK-STAT. 2012;1(4):285-291.
48. Fagard R, Metelev V, Souissi I, Baran-Marszak F. STAT3 inhibitors for cancer therapy: Have all roads been explored? JAK-STAT. 2013;2(1):e22882.
49. Zhou J, Shum KT, Burnett JC, Rossi JJ. Nanoparticle-based delivery of RNAi therapeutics: progress and challenges. Pharmaceuticals (Basel). 2013;6(1):85-107.
50. Lee CK, Rao DT, Gertner R, Gimeno R, Frey AB, Levy DE. Distinct requirements for IFNs and STAT1 in NK cell function. J Immunol. 2000;165(7):3571-3577.
51. Hong F, Jaruga B, Kim WH, et al. Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS. J Clin Invest. 2002;110(10):1503-1513.
52. Cui W, Liu Y, Weinstein JS, Craft J, Kaech SM. An interleukin-21-interleukin-10-STAT3 pathway is critical for functional maturation of memory CD81 T cells. Immunity. 2011;35(5):792-805.
53. Siegel AM, Heimall J, Freeman AF, et al. A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory. Immunity. 2011;35(5):806-818.
54. Boyer MW, Waller EK, Bray RA, et al. Cytokine upregulation of the antigen presenting function of acute myeloid leukemia cells. Leukemia. 2000;14(3):412-418.
55. Mohty M, Isnardon D, Blaise D, et al. Identification of precursors of leukemic dendritic cells differentiated from patients with acute myeloid leukemia. Leukemia. 2002;16(11):2267-2274.
56. Mohty M, Olive D, Gaugler B. Leukemic dendritic cells: potential for therapy and insights towards immune escape by leukemic blasts. Leukemia. 2002;16(11):2197-2204.
57. Ustun C, Miller JS, Munn DH, Weisdorf DJ, Blazar BR. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood. 2011;118(19):5084-5095.
58. Norde WJ, Hobo W, Van Der Voort R, Dolstra H. Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention. Blood. 2012;120(4):728-736.
59. Kadowaki N, Kitawaki T. Recent advance in antigen-specific immunotherapy for acute myeloid leukemia. Clin Dev Immunol. 2011;2011:104926.
60. Cheng F, Wang HW, Cuenca A, et al. A critical role for Stat3 signaling in immune tolerance. Immunity. 2003;19(3):425-436.
61. Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 2004;10(1):48-54.
62. Nefedova Y, Cheng P, Gilkes D, et al. Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J Immunol. 2005;175(7):4338-4346.
63. Cohen PA, Koski GK, Czerniecki BJ, et al. STAT3-and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells. Blood. 2008;112(5):1832-1843.
64. Spaner DE, Foley R, Galipeau J, Bramson J. Obstacles to effective Toll-like receptor agonist therapy for hematologic malignancies. Oncogene. 2008;27(2):208-217.
65. Moreira D, Zhang Q, Hossain DM, et al. TLR9 signaling through NF-κB/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells. Oncotarget. 2015;6(19):17302-17313.